Literature DB >> 30139808

ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.

Erika Van Nieuwenhove1,2,3, Stephanie Humblet-Baron1,2, Lien Van Eyck3, Lien De Somer1,3, James Dooley1,2, Thomas Tousseyn4,5, Michael Hershfield6, Adrian Liston7,2, Carine Wouters1,3.   

Abstract

Multicentric Castleman disease (MCD) is a rare entity that, unlike unicentric Castleman disease, involves generalized polyclonal lymphoproliferation, systemic inflammation, and multiple-organ system failure resulting from proinflammatory hypercytokinemia, including, in particular, interleukin-6. A subset of MCD is caused by human herpesvirus-8 (HHV-8), although the etiology for HHV-8-negative, idiopathic MCD (iMCD) cases is unknown at present. Recently, a consensus was reached on the diagnostic criteria for iMCD to aid in diagnosis, recognize mimics, and initiate prompt treatment. Pediatric iMCD remains particularly rare, and differentiation from MCD mimics in children presenting with systemic inflammation and lymphoproliferation is a challenge. We report on a young boy who presented with a HHV-8-negative, iMCD-like phenotype and was found to suffer from the monogenic disorder deficiency of adenosine deaminase 2 (DADA2), which is caused by loss-of-function mutations in CECR1 DADA2 prototypic features include early-onset ischemic and hemorrhagic strokes, livedoid rash, systemic inflammation, and polyarteritis nodosa vasculopathy, but marked clinical heterogeneity has been observed. Our patient's presentation remains unique, with predominant systemic inflammation, lymphoproliferation, and polyclonal hypergammaglobulinemia but without apparent immunodeficiency. On the basis of the iMCD-like phenotype with elevated interleukin-6 expression, treatment with tocilizumab was initiated, resulting in immediate normalization of clinical and biochemical parameters. In conclusion, iMCD and DADA2 should be considered in the differential diagnosis of children presenting with systemic inflammation and lymphoproliferation. We describe the first case of DADA2 that mimics the clinicopathologic features of iMCD, and our report extends the clinical spectrum of DADA2 to include predominant immune activation and lymphoproliferation.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30139808     DOI: 10.1542/peds.2017-2266

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

1.  Childhood Hodgkin Lymphoma: Think DADA2.

Authors:  Fahad Alabbas; Ghaleb Elyamany; Omar Alsharif; Michael Hershfield; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2019-01-14       Impact factor: 8.317

2.  Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.

Authors:  Oskar Schnappauf; Qing Zhou; Natalia Sampaio Moura; Amanda K Ombrello; Drew G Michael; Natalie Deuitch; Karyl Barron; Deborah L Stone; Patrycja Hoffmann; Michael Hershfield; Carolyn Applegate; Hans T Bjornsson; David B Beck; P Dane Witmer; Nara Sobreira; Elizabeth Wohler; John A Chiorini; The American Genome Center; Clifton L Dalgard; Nih Intramural Sequencing Center; Daniel L Kastner; Ivona Aksentijevich
Journal:  J Clin Immunol       Date:  2020-07-08       Impact factor: 8.317

3.  Genotype and Phenotype of Adenosine Deaminase 2 Deficiency: a Report from Saudi Arabia.

Authors:  Fahad Alabbas; Talal Alanzi; Abdulrahman Alrasheed; Mohammed Essa; Ghaleb Elyamany; Abdulrahman Asiri; Sajdi Almutairi; Sulaiman Al-Mayouf; Abdullatif Alenazi; Danyah Alsafadi; Walid Ballourah; Naif Albalawi; Ehab Hanafy; Abdulqader Al-Hebshi; Seham Alrashidi; Fatma Albatniji; Huda Alfaraidi; Tahani Bin Ali; Mansour Al Qwaiee; Maryam AlHilali; Hayam Aldeeb; Ali Alhaidey; Hassan Aljasem; Sami Althubaiti; Abdulrahman Alsultan
Journal:  J Clin Immunol       Date:  2022-10-14       Impact factor: 8.542

Review 4.  Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist.

Authors:  Rakesh Kumar Pilania; Aaqib Zaffar Banday; Saniya Sharma; Rajni Kumrah; Vibhu Joshi; Sathish Loganathan; Manpreet Dhaliwal; Ankur Kumar Jindal; Pandiarajan Vignesh; Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 5.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.

Authors:  Benzeeta Pinto; Prateek Deo; Susmita Sharma; Arshi Syal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-03-31       Impact factor: 2.980

6.  The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.

Authors:  Charlotte Borocco; Claire Ballot-Schmit; Oanez Ackermann; Nathalie Aladjidi; Jeremie Delaleu; Vannina Giacobbi-Milet; Sarah Jannier; Eric Jeziorski; François Maurier; Yves Perel; Christophe Piguet; Eric Oksenhendler; Isabelle Koné-Paut; Caroline Galeotti
Journal:  Orphanet J Rare Dis       Date:  2020-04-17       Impact factor: 4.123

7.  Candidate biomarkers for idiopathic multicentric Castleman disease.

Authors:  Remi Sumiyoshi; Tomohiro Koga; Atsushi Kawakami
Journal:  J Clin Exp Hematop       Date:  2022

Review 8.  The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency.

Authors:  Jennifer Lee Kendall; Jason Michael Springer
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

9.  Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease.

Authors:  Yushiro Endo; Tomohiro Koga; Yoshihumi Ubara; Remi Sumiyoshi; Kaori Furukawa; Atsushi Kawakami
Journal:  Clin Exp Immunol       Date:  2021-07-26       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.